These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 447438)

  • 41. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.
    Regeur L; Colding H; Jensen H; Kampmann JP
    Antimicrob Agents Chemother; 1977 Feb; 11(2):214-8. PubMed ID: 848923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modification in the pharmacokinetics of amikacin during development.
    Lanao JM; Dominguez-Gil A; Dominguez-Gil AA; Málaga S; Crespo M; Nuño F
    Eur J Clin Pharmacol; 1982; 23(2):155-60. PubMed ID: 7140805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive pharmacokinetics of amikacin using actually measured and assumed parameters, applied in 1-compartment linear pharmacokinetics.
    De Mey C; Scharpe S; De Bock R; Bossaert L
    Arch Int Pharmacodyn Ther; 1981 Oct; 253(2):323-4. PubMed ID: 7325770
    [No Abstract]   [Full Text] [Related]  

  • 44. Behavior of amikacin in renal parenchyma of normal rats and of rats with acute obstructive renal insufficiency.
    Rudhardt M; Fabre J
    Nephron; 1979; 24(6):287-91. PubMed ID: 514429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.
    French MA; Cerra FB; Plaut ME; Schentag JJ
    Antimicrob Agents Chemother; 1981 Jan; 19(1):147-52. PubMed ID: 7247354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment.
    Garcia MJ; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    Biopharm Drug Dispos; 1981; 2(3):205-13. PubMed ID: 7295878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.
    Yasuhara H; Kobayashi S; Sakamoto K; Kamijo K
    J Clin Pharmacol; 1982; 22(8-9):403-9. PubMed ID: 7130429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function.
    Höffler D; Koeppe P; Demers HG
    J Infect Dis; 1976 Nov; 134 SUPPL():S369-73. PubMed ID: 993628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Oksenhendler G; Fillastre JP
    Antibiot Chemother (1971); 1978; 25():163-80. PubMed ID: 352252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetics and dose calculations of amikacin in the newborn.
    Sardemann H; Colding H; Hendel J; Kampmann JP; Hvidberg EF; Vejlsgaard R
    Clin Pharmacol Ther; 1976 Jul; 20(1):59-66. PubMed ID: 1277725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum levels and urinary concentrations of kanamicin, bekanamicin and amikacin (BB-K8) in diabetic children and a control group.
    García G; de Vidal EL; Trujillo H
    J Int Med Res; 1977; 5(5):322-9. PubMed ID: 913860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of cephacetrile in patients undergoing haemodialysis.
    Dominguez-Gil A; Lanao JM; Tabernero JM; Rodriguez Commes JL; de Castro S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):49-52. PubMed ID: 499300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Studies on the toxicity of amikacin (BB-K8),III. Subacute toxicity of amikacin (BB-K8) in dogs (author's transl)].
    Matsuzaki M; Akutsu S; Yoshida A; Onodera K; Sekino M
    Jpn J Antibiot; 1975 Aug; 28(4):458-84. PubMed ID: 1160143
    [No Abstract]   [Full Text] [Related]  

  • 54. The necessity of increased doses of amikacin in burn patients.
    Zaske DE; Sawchuk RJ; Strate RG
    Surgery; 1978 Nov; 84(5):603-8. PubMed ID: 715674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of absorption and excretion of powdery preparation for injection and liquid preparation of BB-K8 (amikacin) (author's transl)].
    Okubo H; Okamoto Y; Uba F; Ueda Y; Ueda T
    Jpn J Antibiot; 1975 Jun; 28(3):283-7. PubMed ID: 1152282
    [No Abstract]   [Full Text] [Related]  

  • 56. Amikacin serum concentrations: prediction of levels and dosage guidelines.
    Sarubbi FA; Hull JH
    Ann Intern Med; 1978 Nov; 89(5 Pt 1):612-8. PubMed ID: 717929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amikacin pharmacokinetics in pediatric patients with malignancy.
    Cleary TG; Pickering LK; Kramer WG; Culbert S; Frankel LS; Kohl S
    Antimicrob Agents Chemother; 1979 Dec; 16(6):829-32. PubMed ID: 533263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological evaluation of amikacin in neonates.
    Howard JB; McCracken GH
    Antimicrob Agents Chemother; 1975 Jul; 8(1):86-90. PubMed ID: 1164009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.
    Péchère JC; Dugal R
    J Infect Dis; 1976 Aug; 134 Suppl():S118-24. PubMed ID: 972269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disposition studies with amikacin after rapid intravenous and intramuscular administration to human volunteers.
    Yates RA; Mitchard M
    J Antimicrob Chemother; 1978 Jul; 4(4):335-41. PubMed ID: 690033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.